ClinicalTrials.gg
Active, not recruitingNCT04959448AROMAUpdated Jul 13, 2026

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

An observational study in Chronic Rhinosinusitis With Nasal Polyposis, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 81 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Regeneron Pharmaceuticals · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
717
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 71 studies in Rhinosinusitis with a site in United States — 11 open to participants now, 18 under way, 7 of them phase 3. Rhinosinusitis · United States.

Enrollment
3rd of 16
717 · median 70
Started
2021
with 4 others
Observational
16 of 71
3 open now
Primary completion
2027-03
later than 7 of 17 live
Registered
48th of 71
by date

Among the 71 studies in Rhinosinusitis with a site in United States, this one is the 3rd largest by enrollment of the 16 observational ones that give a count, is one of 5 that started in 2021, is one of 16 observational ones, reaches primary completion later than 7 of the 17 other live ones, and was the 48th registered.

Rhinosinusitis

252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

11 of the 71 studies in Rhinosinusitis with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Rhinosinusitis with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of the study are:

  • To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time.
  • To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities

The secondary objectives of the study are:

  • To characterize real-world utilization of DUPIXENT® for patients with CRSwNP
  • To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP
  • To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP
03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyposis

Browse trials for

Keywords

  • CRSwNP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are initiating treatment with DUPIXENT® for CRSwNP according to the country-specific prescribing information.

Eligibility criteria

Key Inclusion Criteria:

  • All patients who are newly initiated on DUPIXENT® for the treatment of CRSwNP according to the respective prescribing information (Product Label or SmPC)
  • Willing and able to comply with clinic visits and study-related procedures as per protocol
  • Provide signed by study patient or legally acceptable representative
  • Able to understand and complete study-related questionnaires as per protocol

Key Exclusion Criteria:

  • Patients who have a to DUPIXENT® according to the country-specific prescribing information
  • Any previous treatment with DUPIXENT® for any condition
  • Any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study per protocol
  • Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study per protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
717 participants (actual)
Patient registry
No

Interventions

  • No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.

    Also known as: dupilumab, REGN668, SAR231893

06

What researchers measure

Primary outcomes

  1. Baseline Patient Characteristics

    Demographics includes but is not limited to gender, age, ethnicity, height, weight, BMI, education, current employment status, physician information.

    Time frame: Baseline up to 3 years

  2. Baseline Disease Characteristics

    Medical History includes but is not limited to history of CRSwNP, comorbid conditions, age at CRSwNP diagnosis, and baseline measurements of effectiveness variables.

    Time frame: Baseline up to 3 years

Secondary outcomes

  1. DUPIXENT® Treatment Characteristics

    Including but not limited to: usage, dosage, adherence, interruption, place (home or clinic) and frequency of administration

    Time frame: Baseline up to 3 years

  2. CRSwNP Treatment Characteristics

    Including but not limited to: usage, dosage, adherence, duration and frequency

    Time frame: Baseline up to 3 years

  3. Incidence and severity of adverse events (AEs)

    Time frame: Baseline up to 3 years

  4. Participant Assessment: Total symptom score (TSS), including sub-scores (nasal congestion [NC] and loss of smell [LOS])

    The TSS is a composite score (ranging between 0 and 9) and consisting of the sum of the following symptoms assessed daily: nasal congestion/obstruction, decreased/loss of sense of smell, rhinorrhea (average of anterior/posterior nasal discharge). Higher scores indicate greater symptom burden.

    Time frame: Baseline up to 3 years

  5. Physician Assessment: Change in University of Pennsylvania Smell Identification Test (UPSIT) score

    The UPSIT (UPSIT 40-odorant test) is a rapid and easy-to-administer method to quantitatively assess human olfactory function.

    Time frame: Baseline up to 3 years

  6. Physician Assessment: CT-Lund-Mackay Score

    The LMK system is scoring based on CT imaging of the sinuses with points given for degree of opacification: 0 = no opacification, 1 = partial opacification, 2 = total opacification. These points are then applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side. The ostiomeatal complex is graded as 0 = not occluded, or 2 = occluded. The sum of these derives a maximum score of 12 per side and 24 in total.

    Time frame: Baseline up to 3 years

  7. Physician Assessment: Nasal Peak Inspiratory Flow (PNIF)

    Nasal peak inspiratory flow (NPIF) is a measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute.

    Time frame: Baseline up to 3 years

  8. Physician Assessment: - Forced Expiratory Volume in 1 second (FEV1)

    Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled in the first second of a forced exhalation

    Time frame: Baseline up to 3 years

  9. Physician Assessment: Fractional exhaled Nitric Oxide (FeNO)

    FeNO (Fractional exhaled Nitric Oxiide) is analyzed using a respiratory flow rate of 50 mL/second and reported in ppb.

    Time frame: Baseline up to 3 Years

  10. Participant Assessment: Asthma Control Questionnaire, 6-item (ACQ-6)

    The ACQ-6 assesses asthma control with scores ranging from 0 (fully controlled; 6=severely uncontrolled).

    Time frame: Baseline up to 3 Years

  11. Participant Assessment: Mini Asthma Quality of Life Questionnaire (MiniAQLQ)

    The MiniAQLQ is assesses the impact of asthma on health-related quality of life with scores ranging from 1 (maximum impairment) to 7 (no impairment).

    Time frame: Baseline up to 3 Years

  12. Participant Assessment: Allergic Rhinitis (AR) using AR Visual Analog Scale (VAS)

    The AR-VAS assesses severity of rhinosinusitis symptoms on a 0 (not troublesome) to 10 (worst thinkable troublesome) scale.

    Time frame: Baseline up to 3 Years

  13. Participant Assessment: Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ)

    The MiniRQLQ is an abbreviated version of the RQLQ(S)+12 which assesses health-related quality of life associated with perennial or seasonal allergic rhinitis with scores ranging from 0 (not troubled) to 6 (extremely troubled).

    Time frame: Baseline up to 3 Years

  14. Participant Assessment: Sino-Nasal Outcome Test (SNOT-22)

    The SNOT-22 assesses the impact of chronic rhinosinusitis on health-related quality of life with scores ranging from 0 to 110; lower scores representing better health related quality of life.

    Time frame: Baseline up to 3 Years

  15. Participant Assessment: Patient Oriented Eczema Measure (POEM)

    The POEM assesses symptoms of dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping with scores ranging from 0 to 28; higher scores indicate greater symptom burden.

    Time frame: Baseline up to 3 Years

  16. Participant Assessment: Work Productivity and Activity Impairment Questionnaire for asthma (WPAI-CRSwNP)

    The WPAI-CRSwNP measures impairments in work and activities associated with CRSwNP. Scores are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

    Time frame: Baseline up to 3 Years

  17. Physician Assessment: Changes of Healthcare Utilization

    Resource use collected from medical, hospital, and pharmacy records

    Time frame: Baseline up to 3 years

  18. Participant Assessment: Short Form 12

    The SF-12 assesses physical functioning, social functioning, role limitations due to physical problems, role limitations due to emotional problems, mental health, energy/vitality, pain, and general health perception with scores ranging from 0 to 100; lower scores represent greater quality of life impairment.

    Time frame: Baseline up to 3 years

  19. Participant Assessment: European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)

    The EQ 5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and the EQ-VAS records the respondent's self rated health on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline up to 3 years

  20. Participant Assessment: Global Impression for Symptom Severity, Treatment Satisfaction (Global Patient Assessment)

    The Global Patient Assessment is a 2-component questionnaire on symptom severity over the past week and the patient's overall satisfaction with their CRSwNP treatment.

    Time frame: Baseline up to 3 years

  21. Physician Assessment: Global Impression for Disease Severity (Global Physician Assessment)

    The Global Physician Assessment is a 1-item question asking physicians to rate the severity of their patient's CRSwNP.

    Time frame: Baseline up to 3 years

07

Study locations

81 sites
08

References and documents

Publications

  • Peters AT, Shah R, Heffler E, Wagenmann M, Fujieda S, Xia C, Nash S, Clotz M, Corbett M, Radwan A. Baseline disease characteristics among patients with chronic rhinosinusitis with nasal polyps in AROMA: A global registry study. Allergy Asthma Proc. 2025 Sep 1;46(5):414-421. doi: 10.2500/aap.2025.46.250055. PubMed 40958188 ↗
  • Siddiqui S, Bachert C, Chaker AM, Han JK, Hellings PW, Peters AT, Heffler E, Kamat S, Zhang H, Nash S, Khan AH, De Prado Gomez L, Jacob-Nara JA, Rowe PJ, Deniz Y. AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps. ERJ Open Res. 2022 Nov 28;8(4):00085-2022. doi: 10.1183/23120541.00085-2022. eCollection 2022 Oct. PubMed 36451848 ↗

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Mar 2027, 67 months after the start.

Of 22 observational studies under Rhinosinusitis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 71. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jul 13, 2021
StartActual
Aug 12, 2021
Primary completionEst.
Mar 25, 2027
CompletionEst.
Mar 25, 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04959448
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jul 13, 2021
Start date
Aug 12, 2021
Primary completion
Mar 25, 2027 (estimated)
Completion
Mar 25, 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion